Targeted therapy of urological tumours. Experimental field or established therapeutic approach?;Die target-therapie urologischer tumoren : Experimentierfeld oder etablierter therapeutischer ansatz?

Urologe - Ausgabe A

Volumn 49, Issue 10, 2010, Pages 1260-1265

  Kramer, M W ^a   Krege, S ^b   Peters, I ^a   Merseburger, A S ^a   Kuczyk, M A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Krankenhaus Maria Hilf   (Germany)

Author keywords

Current status; Targeted therapy; Urological cancer

Indexed keywords

BLADDER CANCER; CANCER CHEMOTHERAPY; CELL DIVISION; CLINICAL EFFECTIVENESS; DISEASE COURSE; EXPERIMENTAL STUDY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MOLECULARLY TARGETED THERAPY; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; URINARY TRACT CANCER; URINARY TRACT TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TESTICULAR NEOPLASMS; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 77958490211     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-010-2397-2     Document Type: Review

References (43)

1. Escudier B, Eisen T, Stadler WM et al (2007) Sorafe¬nib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
2. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111
3. Szczylik C (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. Abstract ASCO Annual Meeting
4. Hudes G, Carducci M, Tomczak P et al (2007) Tem¬sirolimus, interferon alfa, or both for advanced re¬nal-cell carcinoma. N Engl J Med 356:2271-2281
5. Motzer R, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcino¬ma: final results and analysis of prognostic factors. Cancer (in press)
6. Motzer RJ, Hutson TE, Tomczak P et al (2009) Over¬all survival and updated results for sunitinib com¬pared with interferon alfa in patients with metas¬tatic renal cell carcinoma. J Clin Oncol 27:3584-3590
7. Escudier BJ (2009) Final results of the phase III, ran¬domized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in me¬tastatic renal cell carcinoma (mRCC). Abstract AS¬CO Annual Meeting
8. Rini BI (2009) Bevacizumab plus interferon-al¬pha versus interferon-alpha monotherapy in pati¬ents with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. Abstract ASCO Annual Meeting
9. Motzer RJ, Hutson TE, Tomczak P et al (2007) Suni¬tinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
10. Patard J-J, Rioux-Leclercq N, Fergelot P (2006) Un¬derstanding the importance of smart drugs in re¬nal cell carcinoma. Eur Urol 49:633-643
11. Peters I, Rehmet K, Wilke N et al (2007) RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer 6:49
12. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazo¬panib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068
13. Picus J (2003) The use of bevacizumab with do¬cetaxel and estramustine in hormone refracto¬ry prostate cancer (HRPC): initial results of CALGB 900006. Abstract ASCO Annual Meeting
14. Kelly WK (2010) A randomized, double-blind, pla¬cebo-controlled phase III trial comparing doce¬taxel, prednisolone, and placebo with doceta¬xel, prednisolone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. Abstract ASCO Annual Meeting
15. Aaragon-Ching JB, Jain L, Gulley JL et al (2009) Fi¬nal analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 103:1636-1640
16. Dror Michaelson M, Regan MM, Oh WK et al (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 97:913-920
17. Dahut WL, Scripture C, Posadas E et al (2008) A phase II clinical trial of sorafenib in androgen-inde¬pendent prostate cancer. Clin Cancer Res 14:209-214
18. Azad NS, Aaragon-Ching JB, Dahut WL et al (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15(4):1411-1416
19. Maase H von der, Sengelov L, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotre¬xate, vinblastine, doxorubicin, and cisplatin in ad¬vanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
20. Chia-Chi L, Chih-Hung H, Yeong-Shiau P et al (2007) Systemic therapy for metastatic urothelial carcinoma. BJU Int 101:795-803
21. Jimenez RE, Hussain M, Bianco FJ Jr et al (2001) Her-2/neu overexpression in muscle-invasive uro¬thelial carcinoma of the bladder: Prognostic signi¬ficance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440-2447
22. Chow NH, Liu HS, Lee El et al (1997) Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 17:1293-1296
23. Izawa Jl, Slaton JW, Kedar D et al (2001) Differenti¬al expression of progression-related genes in the evolution of superficial to invasive transitional cell carcioma of the bladder. Oncol Rep 8:9-15
24. King CR, Kraus MH, Aaronson SA (1986) Amplifi¬cation of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976
25. Hussain M, Petrylak D, Dunn R et al (2005) Tras¬tuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced Her2-positive uro¬thelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Oncol 23(Suppl 16):379
26. Nguyen PL, Swanson PE, Jaszcz W et al (1994) Ex¬pression of epidermal growth factor receptor in in¬vasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 101:166-176
27. Petrylak D, Faulkner JR, Van Veldhuizen PJ et al (2003) Evaluation of ZD1839 for advanved tran¬sitinal cell carcinoma (TCC) of the urothelium: A Southwest Oncology Group trial. Proc Am Soc Clin Oncol 22:403 (abstract 1619)
28. Yang CC, Chu KC, Yeh WM (2004) The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22:1-6
29. Bellmunt J, Gonzalez-Larriba L, Maroto JP et al (2010) First-line treatment with sunitinib mono¬therapy in patients with advanced urothelial can¬cer ineligible for ciplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit. J Clin Oncol 28:351
30. Galsky MD, Sonpavde G, Hellerstedt BA et al (2010) Phase II study of gemcitabine, cisplatin, and suni¬tinib in patients with advanced urothelial carcino¬ma (UC). J Clin Oncol 28:360
31. Krege S, Rexer H, Dorp F vom et al (2010) Gemci¬tabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). J Clin Oncol 28:360
32. Hahn NM, Stadler WM, Zon R et al (2010) Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). J Clin Oncol 28:352
33. International Germ Cell Cancer Collaboration Group (IGCCCG) (2002) The International Germ Cell Consensus Classification: a prognostic factor ba¬sed staging sytem for metastatic germ cell cancer. J Clin Oncol 20:4448-4452
34. Beyer J, Stenning S, Gerl A et al (2002) High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-semino¬matous germ-cell tumors: a matched-pair analysis. Ann Oncol 13:599-605
35. Einhorn LH, Williams SD, Chamness A et al (2007) High-dose chemotherapy and stemm-cell res¬cue for metastatic germ-cell tumors. N Engl J Med 357:340-348
36. Famarkis D, Pectasides M, Pectasides D (2005) Re¬cent advances in conventional-dose salvage che¬motherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors. Eur Urol 48:400-407
37. Henley J, Einhorn LH (1999) C-erbB-2 (Her-2-neu) overexpression in recurrent ger-cell tumors. Proc Am Soc Clin Oncol 18:341
38. Kollmannsberger C, Pressler H, Mayer F et al (1999) Cisplatin-refractory, Her2/neu-expressing germ-cell cancer: induction of remission by the monoc¬lonal antibody Trastuzumab. Ann Oncol 10:1393-1394
39. Wang X, Zhang S, MacLennan GT et al (2009) Epi¬dermal growth factor receptor protein expressi¬on and gene amplification in the chemorefracto¬ry metastatic embryonal carcinoma. Mod Pathol 22:7-12
40. Kemmer K, Corless CL, Fletcher JA et al (2004) KIT mutations are common in testicular seminomas. Am J Pathol 164:305-313
41. Einhorn LH, Brames MJ, einrich MC et al (2006) Phase II study of imatinib mesylate in chemothera¬py refractory germ cell tumors expressing KIT. Am J Clin Oncol 29:12-13
42. Kollmannsberger CK, Oechsle K, Cheng T et al (2010) Sunitinib in patients with multiply relapsed or sicplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study. J Clin Oncol 28:362
43. Calaminus G, Schneider DT, Weissbach L et al (2009) Survival after an antiangiogenetic thera¬py and surgery in a wide spread growing terato¬ma originating from a testicular mixed malignant germ cell tumor. Klin Pediatr 221:134-135